Does NCT05652894 meet its primary endpoint at primary completion?

85% likely to meet · workos:user_01KSZTKKXBYCCV0QQHTN6WP9S8

target PD-1 · moa checkpoint-inhibition · failure mode none

1. premise MSI-H/dMMR colorectal tumors carry an exceptionally high neoantigen load, making them the canonical checkpoint-responsive colorectal subset where T-cell recognition is the rate-limiting step that PD-1 blockade relieves
2. premise In the identical 1L MSI-H/dMMR mCRC setting, pembrolizumab monotherapy roughly doubled progression-free survival versus chemotherapy in KEYNOTE-177 (median ~16.5 vs ~8.2 months, HR ~0.60) nct:NCT02563002 pmid:33264544
3. premise The same class benefit was independently reproduced with nivolumab with or without ipilimumab versus chemotherapy in 1L MSI-H/dMMR mCRC in CheckMate-8HW
4. inference Pucotenlimab is another anti-PD-1 tested in the same biomarker-locked 1L population against a chemotherapy comparator, so it engages the exact rate-limiting step already shown twice to be unlockable by the class; this is mechanism replication, not a new bet
5. prediction PFS by IRC is met in the intended direction with HR below 0.7

Evidence: nct:NCT02563002, pmid:33264544